Algorithm of treatment of patients with castrate-resistant prostate cancer: modern concept and perspectives

Algorithm of treatment of patients with castrate-resistant prostate cancer: modern concept and perspectives

Prostate cancer is one of the most actual problems of modern oncourology. Castrate-refractory prostate cancer (CRPC) is extremely he-terogeneous disease and treatment conception should be individualized in every patient. Therapeutic options in CRPC include 2nd line hormonal therapy, chemotherapy, va...

Full description

Bibliographic Details
Main Authors:	B Ya Alekseev, K M Nyushko, A S Kalpinskiy, A D Kaprin
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2014-06-01
Series:	Современная онкология
Subjects:	castrate-resistant prostate cancer chemotherapy hormonal therapy treatment algorithm prognostic factors
Online Access:	https://modernonco.orscience.ru/1815-1434/article/view/26952

Similar Items

Second line chemotherapy in patients with castration-refractory prostate cancer. Ftom clinical studies to practice
by: B. Ya. Alekseev, et al.
Published: (2019-04-01)

Prospects of 2nd line chemotherapy personalization in patients with metastatic castration-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2016-12-01)

Second-line hormonal therapy with the enzalutamid in patients with castrate-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2016-09-01)

The National Registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation
by: O. B. Karyakin, et al.
Published: (2019-10-01)

Diferelin® as an effective chemical castration agent for patients with prostate cancer
by: K. M. Nyushko, et al.
Published: (2021-02-01)

Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis
by: Gianpaolo Perletti, et al.
Published: (2015-07-01)

THE POSSIBILITIES AND MECHANISMS OF ACTION OF HORMONE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

THE POSSIBILITIES AND MECHANISMS OF ACTION OF HORMONE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev
Published: (2018-10-01)

Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer
by: B. Ya. Alexeev, et al.
Published: (2018-11-01)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01)

Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
by: Geehyun Song, et al.
Published: (2013-09-01)

Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer
by: Yi-Ping Zhu, et al.
Published: (2014-02-01)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
by: Minyong Kang, et al.
Published: (2015-12-01)

Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies
by: K. M. Nyushko, et al.
Published: (2014-12-01)

Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies
by: K. M. Nyushko, et al.
Published: (2014-12-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Evaluation of the efficacy and safety of cabazitaxel in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have previously received docetaxel chemotherapy in daily clinical practice. Results of a Russian multicenter prospective study
by: B. Ya. Alekseev, et al.
Published: (2020-04-01)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
by: Atsushi Mizokami, et al.
Published: (2017-01-01)

Alpha-therapy using radium-223 chloride in patients with castration-resistant prostate cancer. From clinical researches to routine practice
by: K. M. Nyushko, et al.
Published: (2020-01-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
by: Magdalena Schrank, et al.
Published: (2020-01-01)

Muscle Characteristics Obtained Using Computed Tomography as Prognosticators in Patients with Castration-Resistant Prostate Cancer
by: Jongsoo Lee, et al.
Published: (2020-07-01)

Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide
by: B. Ya. Alekseyev, et al.
Published: (2019-12-01)

New developments in the treatment of castration resistant prostate cancer
by: Roxanne Wadia, et al.
Published: (2014-08-01)

THERAPY WITH SOMATOSTATIN ANALOGUES IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER
by: K. Y. Kanukoev, et al.
Published: (2015-04-01)

Experimental study of apoptosis in the prostate tissue following castration
by: Y Doustar, et al.
Published: (2008-02-01)

THE ATYPICAL SITE OF URETERAL METASTASIS IN A PATIENT WITH CASTRATION-REFRACTORY PROSTATE CANCER. A CLINICAL CASE AND A REVIEW OF LITERATURE
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

THE ATYPICAL SITE OF URETERAL METASTASIS IN A PATIENT WITH CASTRATION-REFRACTORY PROSTATE CANCER. A CLINICAL CASE AND A REVIEW OF LITERATURE
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

Tumor lysis syndrome following cabazitaxel administration for metastatic castration‐resistant prostate cancer: A case report
by: Masashi Oshima, et al.
Published: (2019-07-01)

Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients
by: Mark A. Underwood, et al.
Published: (2013-08-01)

HORMONE THERAPY WITH USAGE OF AGONISTS AND ANTAGONISTS OF LUTEINIZING HORMONE RELEASING HORMONE IN PATIENTS WITH PROSTATE CANCER
by: K. M. Nyushko, et al.
Published: (2015-01-01)

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
by: Pascoe Abigail C, et al.
Published: (2012-03-01)

Radium-223 in treatment of castration-resistant prostate cancer with skeletal metastases
by: V. B. Matveev, et al.
Published: (2017-10-01)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
by: Michael W. Kattan, et al.
Published: (2020-11-01)

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
by: A. V. Rudakova, et al.
Published: (2014-11-01)

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
by: A. V. Rudakova, et al.
Published: (2014-11-01)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
by: Tucci M, et al.
Published: (2018-10-01)

Current opportunities of therapy for patients with non-metastatic castration-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2020-11-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Cannot write session to /tmp/vufind_sessions/sess_aqro2mvpbmhjtqgknl3kvnob06